Polaryx Therapeutics Welcomes New Members of the Board of Directors
Polaryx Therapeutics, Inc. (PLYX)
Company Research
Source: GlobeNewswire
PARAMUS, NJ, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX) a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”), today announces the appointments of Mitchel Berger, M.D., Francis A. Braun III, CPA, and Charles Ryan, J.D., Ph.D. to Polaryx’s Board of Directors, effective January 29, 2026. In addition, Andrew O ceased serving as a member of the Board effective on the same date. Polaryx believes the addition of Dr. Berger, Mr. Braun, and Dr. Ryan brings valuable expertise across scientific research, clinical development, finance, and corporate strategy, strengthening the Board as Polaryx advances as a public company. These appointments come at a pivotal time for Polaryx, as its lead candidate, PLX-200, advances into an IND-approved SOTERIA Phase 2 basket trial, representing a key near-term milestone. “We are trul
Show less
Read more
Impact Snapshot
Event Time:
PLYX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PLYX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PLYX alerts
High impacting Polaryx Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
PLYX
News
- Polaryx Therapeutics Receives FDA Fast Track Designation for PLX-200 for Late-Infantile Neuronal Ceroid Lipofuscinosis (CLN2 Disease) [Yahoo! Finance]Yahoo! Finance
- Polaryx Therapeutics Receives FDA Fast Track Designation for PLX-200 for Late-Infantile Neuronal Ceroid Lipofuscinosis (CLN2 Disease)GlobeNewswire
- Polaryx Therapeutics Deepens Engagement with the Krabbe Disease Community Through Scientific and Patient Advocacy EventsGlobeNewswire
- Polaryx Therapeutics Marks Rare Disease Day, Reaffirming Commitment to Patients with Rare Pediatric Lysosomal Storage Disorders [Yahoo! Finance]Yahoo! Finance
- Polaryx Therapeutics (PLYX) is now covered by Maxim Group. They set a "buy" rating and a $10.00 price target on the stock.MarketBeat
PLYX
Sec Filings
- 3/24/26 - Form 10-K
- 2/20/26 - Form 4
- 2/5/26 - Form SCHEDULE
- PLYX's page on the SEC website